Last reviewed · How we verify
Placebo- Sinemet
Sinemet is a combination of carbidopa and levodopa, which work together to increase dopamine levels in the brain.
Sinemet is a combination of carbidopa and levodopa, which work together to increase dopamine levels in the brain. Used for Parkinson's disease, Parkinson's disease with fluctuations.
At a glance
| Generic name | Placebo- Sinemet |
|---|---|
| Sponsor | Intec Pharma Ltd. |
| Drug class | Dopamine agonist |
| Target | Dopamine receptors |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
Carbidopa inhibits the conversion of levodopa to dopamine outside the brain, allowing more levodopa to cross the blood-brain barrier and increasing dopamine levels in the brain. This helps to alleviate symptoms of Parkinson's disease, such as tremors and stiffness.
Approved indications
- Parkinson's disease
- Parkinson's disease with fluctuations
Common side effects
- Nausea
- Vomiting
- Dizziness
- Headache
- Fatigue
Key clinical trials
- Dopaminergic Dysfunction in Late-Life Depression (PHASE2)
- Dopaminergic Therapy for Anhedonia - 2 (PHASE4)
- Pharmacological Agents for Chronic Spinal Cord Injury (SCI) (PHASE1)
- Neurobiological Drivers of Mobility Resilience: The Dopaminergic System - Placebo-Controlled Arm (PHASE1, PHASE2)
- Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations (PHASE3)
- Treating Early Stage Diabetic Retinopathy (EARLY_PHASE1)
- A Study to Evaluate the Efficacy and Safety of HRG2010 in Parkinson's Disease With Motor Fluctuations (PHASE3)
- Dopaminergic Enhancement of Rehabilitation Therapy Early After Stroke (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo- Sinemet CI brief — competitive landscape report
- Placebo- Sinemet updates RSS · CI watch RSS
- Intec Pharma Ltd. portfolio CI